Application of T1-T2 dual-mode cobalt manganese oxide nanoparticle MRI contrast agent in the diagnosis of oral squamous cell carcinoma

doi:10.19439/j.sjos.2026.01.002

Abstract

Abstract: PURPOSE: To develop an efficient and low-toxicity T1-T2 dual-mode magnetic resonance (MR) nano-contrast agent (cobalt manganese oxide @hyaluronic acid, CMO@HA) as a safe and effective strategy for the diagnosis of oral squamous cell carcinoma (OSCC). METHODS: CMO@HA was synthesized via a multi-step process and characterized for its morphology and composition using transmission electron microscopy(TEM) and X-ray diffraction (XRD). MR imaging of CMO@HA suspensions at various concentrations was performed to acquire T1- and T2-weighted images and relaxation times. The longitudinal and transverse relaxivities were calculated using linear regression analysis. A xenograft mouse model was established to evaluate the in vivo tumor imaging performance of CMO@HA. Biocompatibility was assessed through CCK-8 cell viability assays, live-dead cell staining and HE staining of major organs. RESULTS: CMO@HA was successfully synthesized with an average particle size of approximately 12 nm and a zeta potential of -16.6 mV. In MRI, CMO@HA solutions exhibited concentration-dependent T1-T2 dual-enhanced imaging characteristics, with longitudinal and transverse relaxivities of 1.005 (mmol/L)^-1s^-1 and 11.84 (mmol/L)^-1s^-1, respectively. In the xenograft mouse model, intratumoral injection of CMO@HA resulted in an enhancement of T1-weighted and T2-weighted signals at the tumor site by (46.98±14.51)% and (26.04±6.9)%, respectively. Biocompatibility assessments revealed that after co-incubation with 100 μg/mL CMO@HA, the cell viability remained at 98%, live-dead staining results showed no significant differences compared to the control group. During a 7-day observation period, CMO@HA-treated mice exhibited stable body weights comparable to the control group, and no pathological damage or liver and kidney dysfunction was observed in major organs. CONCLUSIONS: CMO@HA is a nano-contrast agent with excellent T1-T2 dual-mode MR imaging enhancement capabilities and favorable biocompatibility. It significantly improves the imaging contrast between tumor and normal tissues, providing a viable imaging solution for early diagnosis of OSCC.

Key words: Oral squamous cell carcinoma, Tumor imaging, Cobalt manganese oxide nanoparticles, MRI contrast agent

CLC Number:

R739.8

Xu Hongtao, Cheng Han, Li Fangjie, Zheng Chongyang, Huang Xiaojuan, Zhang Zhiyuan. Application of T1-T2 dual-mode cobalt manganese oxide nanoparticle MRI contrast agent in the diagnosis of oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2026, 35(1): 7-12.

References

[1] Wang B, Zhang S, Yue K, et al.The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases[J]. Chin J Cancer, 2013, 32(11): 614-618.
[2] Bachmann AS, Zaunbauer AC, Tolke AM, et al.Well-being and quality of life among oral cancer patients - psychological vulnerability and coping responses upon entering initial treatment[J]. J Craniomaxillofac Surg, 2018, 46(9): 1637-1644.
[3] Baykul T, Yilmaz HH, Aydin U, et al.Early diagnosis of oral cancer[J]. J Int Med Res, 2010, 38(3): 737-749.
[4] Sarrión Pérez MG, Bagán JV, Jiménez Y, et al.Utility of imaging techniques in the diagnosis of oral cancer[J]. J Craniomaxillofac Surg, 2015, 43(9): 1880-1894.
[5] Pfister DG, Spencer S, Adelstein D, et al.Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(7): 873-898.
[6] Thoenissen P, Heselich A, Burck I, et al.The role of magnetic resonance imaging and computed tomography in oral squamous cell carcinoma patients' preoperative staging[J]. Front Oncol, 2023, 13: 972042.
[7] Touska P, Connor SEJ.Recent advances in MRI of the head and neck, skull base and cranial nerves: new and evolving sequences, analyses and clinical applications[J]. Br J Radiol, 2019, 92(1104): 20190513.
[8] Al-Haj Husain A, Schmidt V, Valdec S, et al. MR-orthopantomography in operative dentistry and oral and maxillofacial surgery: a proof of concept study[J]. Sci Rep, 2023, 13(1): 6228.
[9] Popov AL, Abakumov MA, Savintseva IV, et al.Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells[J]. J Mater Chem B, 2021, 9(33): 6586-6599.
[10] Jin R, Lin B, Li D, et al.Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications[J]. Curr Opin Pharmacol, 2014, 18: 18-27.
[11] Heidkamp J, Weijs WLJ, van Engen-van Grunsven ACH, et al. Assessment of surgical tumor-free resection margins in fresh squamous-cell carcinoma resection specimens of the tongue using a clinical MRI system[J]. Head Neck, 2020, 42(8): 2039-2049.
[12] Singh A, Thukral CL, Gupta K, et al.Role of MRI in evaluation of malignant lesions of tongue and oral cavity[J]. Pol J Radiol, 2017, 82: 92-99.
[13] Cao X, Gu L, Hu S, et al.Fe/Mn multilayer nanowires as high-performance T1-T2 dual modal mri contrast agents[J]. Materials (Basel), 2021, 14(9): 2238.
[14] Yasumoto M, Shibuya H, Takeda M, et al.Squamous cell carcinoma of the oral cavity: MR findings and value of T1-versus T2-weighted fast spin-echo images[J]. AJR Am J Roentgenol, 1995, 164(4): 981-987.
[15] Shin TH, Choi JS, Yun S, et al.T₁ and T₂ dual-mode MRI contrast agent for enhancing accuracy by engineered nanomaterials[J]. ACS Nano, 2014, 8(4): 3393-3401.
[16] Kim MH, Son HY, Kim GY, et al.Redoxable heteronanocrystals functioning magnetic relaxation switch for activatable T1 and T2 dual-mode magnetic resonance imaging[J]. Biomaterials, 2016, 101: 121-30.